Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 2 , Pages 153-157 , March 2008

The use of tumor markers in testis cancer in the United States: A potential quality issue

  • Scott M. Gilbert, M.D.

      Affiliations

    • Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA
    • ,
  • Stephanie Daignault, M.S.

      Affiliations

    • Department of Biostatistics, University of Michigan Cancer Center, Ann Arbor, MI 48109, USA
    • ,
  • Alon Z. Weizer, M.D.

      Affiliations

    • Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA
    • ,
  • John T. Wei, M.D., M.S.

      Affiliations

    • Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA
    • ,
  • Brent K. Hollenbeck, M.D., M.S.

      Affiliations

    • Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-734-615-6662; fax: +1-734-936-9127.

Received 10 October 2006 ,Revised 15 December 2006 ,Accepted 21 December 2006.

References 

  1. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348:2635–2645
  2. Institute of Medicine. Performance measurement: Accelerating improvement. Washington D.C: National Academies Press; 2006;
  3. Centers for Medicare and Medicaid Services, Medicare Demonstrations, Medicare Care Management Performance Demonstration, Clinical Quality Measures. http://www.cms.hhs.gov/DemoProjectsEvalRpts/Accessed March 7, 2006
  4. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet. 2006;367:754–765
  5. Schmoll HJ, Souchon R, Krege S, et al. European consensus on the diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004;15:1377–1399
  6. Dearnaley DP, Huddart RA, Horwich A. Regular review: Managing testicular cancer. BMJ. 2006;322:1583–1588
  7. Vastag B. Testicular cancer seen as the “stalking horse” for other cancers. J Natl Cancer Inst. 1999;91:1801–1803
  8. Thomas G, Jones W, Van Oosterom A, et al. Consensus statement on the investigation and management of testicular seminoma 1989. Prog Clin Biol Res. 1990;357:285–294
  9. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem. 2002;48:1151–1159
  10. Stephenson AJ, Bosl GJ, Bajorin DF, et al. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol. 2005;174:557–560
  11. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med. 1997;337:242–254
  12. Zon RT, Nichols C, Einhorn LH. Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol. 1998;16:1294–1297
  13. Overview of the SEER Program, National Cancer Institute Surveillance, Epidemiology, and End Results program description. http://seer.cancer.gov/aboutAccessed February 16, 2006
  14. Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology and end results program: A national resource. Cancer Epidemiol Biomarkers Prev. 1999;8:1117–1121
  15. National Cancer Institute Surveillance, Epidemiology and End Result Program, Information for Cancer Registrars, SEER Coding and Staging Manual 2004, Appendix C, Site-Specific Coding Modules, Part 3. http://seer.cancer.gov/manuals/2004Revision%201/SPM_AppendixC_Part3_r1.pdfAccessed February 16, 2006
  16. American Joint Commission on Cancer (AJCC). AJCC cancer staging manual. 6th ed.. New York (NY): Springer-Verlag; 2002;
  17. National Comprehensive Cancer Network, Practice Guidelines in Oncology—v. 1.2006. Testicular cancer. www.nccn.org/professionals/physician_gls/PDF/testicular.pdfAccessed December 14, 2005
  18. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594–603

☆ S.M.G. is supported by an NIH T32 training grant at the University of Michigan. B.K.H. is supported in part by the John and Suzanne Munn Idea Grant through the University of Michigan Comprehensive Cancer Center.

PII: S1078-1439(07)00002-6

doi: 10.1016/j.urolonc.2006.12.018

Urologic Oncology: Seminars and Original Investigations
Volume 26, Issue 2 , Pages 153-157 , March 2008

Article Tools

* Image Usage & Resolution